NL-OMON42429已完成不适用
A phase 1, randomized, double blind, placebo controlled, multiple ascending dose, safety and pharmacodynamic study of MDV1634 in patients with Parkinson*s disease. - MAD study with MDV1634 in patients with Parkinson*s disease.
Medivation, Inc. and its Subsidiaries0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Male and female volunteers
- •Parkinson disease
- •30-75 years of age
- •BMI 18-35 kg/m2, inclusive
排除标准
- •CYP2D6 genotype indicating poor or intermediate metabolizer status; Montreal Cognitive Assessment score < 24; hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
1 期
To determine the safety, tolerability, uptake and breakdown of single and multiple doses of AS012 in healthy subjects.CTRI/2019/08/020753Sun Pharmaceutical Industries Ltd SPI167
尚未招募
1 期
To evaluate the safety, tolerability and pharmacokinetics of single-dose and multiple-dose administration of MKP 10241CTRI/2021/09/036637Mankind Pharma Limited
已完成
不适用
A Phase 1, Randomized, Double-blind, Placebo controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX*150 in Healthy Male AdultsPain10029305NL-OMON46528Vertex Pharmaceuticals20
已完成
不适用
A phase 1, randomized, double blind, placebo-controlled, single ascending dose study to assess safety, tolerability and pharmacokinetics of cRGD-ZW800-1 intravenous injection in healthy volunteersMalignant tumors10027655CancerNL-OMON43465Centre for Human Drug Research11
已完成
不适用
A phase 1, randomized, double blind, placebo-controlled, single and repeated ascending dose study to assess safety, tolerability and pharmacokinetics of ZW800-1 injected intravenously into healthy volunteersMalignant tumors1002765510038365CancerNL-OMON45587Centre for Human Drug Research16